Universal Beteiligungs und Servicegesellschaft mbH Has $3.91 Million Holdings in Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH raised its position in Catalyst Pharmaceuticals by 30% to 167,763 shares (about $3.91 million), representing roughly 0.14% ownership of the company.
• Institutional investors own about 79.22% of CPRX; the stock has a $3.45 billion market cap, P/E of 16.72, a 52-week range of $19.05–$32.56, and 50-/200-day SMAs near $24.83 and $23.64.
• Analysts have an average rating of "Strong Buy" with a $34.00 consensus target after several recent upgrades, and Catalyst's lead product is Firdapse (amifampridine) for Lambert‑Eaton Myasthenic Syndrome.

Universal Beteiligungs und Servicegesellschaft mbH raised its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 30.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 167,763 shares of the biopharmaceutical company's stock after purchasing an additional 38,695 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned 0.14% of Catalyst Pharmaceuticals worth $3,913,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Rothschild Investment LLC raised its stake in shares of Catalyst Pharmaceuticals by 1,085.7% in the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 1,520 shares during the period. Advisory Services Network LLC acquired a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at about $39,000. Quarry LP acquired a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at about $40,000. Financial Life Planners acquired a new stake in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at about $42,000. Finally, First Horizon Corp acquired a new stake in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $52,000. Institutional investors and hedge funds own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

NASDAQ:CPRX opened at $28.26 on Thursday. The stock's 50-day simple moving average is $24.83 and its 200 day simple moving average is $23.64. The company has a market cap of $3.45 billion, a P/E ratio of 16.72, a P/E/G ratio of 0.85 and a beta of 0.67. Catalyst Pharmaceuticals, Inc. has a 52-week low of $19.05 and a 52-week high of $32.56.

Analyst Upgrades and Downgrades

Several analysts have issued reports on CPRX shares. Zacks Research raised Catalyst Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, March 3rd. Weiss Ratings reissued a "buy (b-)" rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Friday, March 27th. Truist Financial raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, March 25th. Finally, Citigroup lifted their price target on Catalyst Pharmaceuticals from $33.00 to $35.00 and gave the company a "buy" rating in a research note on Tuesday, March 3rd. Three investment analysts have rated the stock with a Strong Buy rating and three have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Strong Buy" and a consensus target price of $34.00.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company's mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company's lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).

Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.